Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma.
about
Tumor antigen-specific monoclonal antibodies and induction of T-cell immunityLate-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry.Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms.Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma.New developments in the management of Waldenström macroglobulinemiaRituximab-related late-onset neutropenia in patients with rheumatic diseases: successful re-challenge of the treatment.Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors.A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer.Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells.Drug-Induced Neutropenia: A Focus on Rituximab-Induced Late-Onset Neutropenia.Single-nucleotide polymorphisms and copy number variations of the FCGR2A and FCGR3A genes in healthy Japanese subjects.Genotypes Affecting the Pharmacokinetics of Anticancer Drugs.Effect of FCGR polymorphism on the occurrence of late-onset neutropenia and flare-free survival in rheumatic patients treated with rituximab.Unexpected hematologic effects of biotherapeutics in nonclinical species and in humans.FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts.Description of late onset neutropenia in indolent lymphoma patients treated with bendamustine plus rituximab.Rituximab for the treatment of follicular lymphoma.Neutropenia in Patients with Common Variable Immunodeficiency: a Rare Event Associated with Severe Outcome.4-1BB ligand modulates direct and Rituximab-induced NK-cell reactivity in chronic lymphocytic leukemia.Risk factors for late-onset neutropenia after rituximab treatment of B-cell lymphoma.The FCGR3A polymorphism predicts the response to rituximab-based therapy in patients with non-Hodgkin lymphoma: a meta-analysis.Pyrosequencing for classification of human FcγRIIIA allotypes: a comparison with PCR-based techniques.
P2860
Q27009908-38DE3417-EFB5-44B5-9326-A71DE0D9D260Q31012265-8BF06DC1-484A-4AF8-8713-BD223227A2D0Q34072947-9E79A0FF-2377-4DAA-B88B-F9410A2113E1Q34194706-136772CA-FB35-40CB-9497-F3B101C070A0Q34212528-3EC6B368-464A-48AB-8F41-5E52EFC348F8Q34553880-E0D8FBE2-CC25-46E1-AE49-421BCB89C6D7Q35531665-A4476D1D-68CF-4C59-8D0E-08C9A76E84C1Q36264895-4AC3D64C-59BF-44E7-A99F-3E9A2083154BQ36547750-5416CF50-12A4-4CCF-B161-04B447DF1AEDQ37362596-B9192DB7-D013-4C9F-BB31-A1F993FEC88BQ37462856-A1FC5339-90F6-4D57-9A95-C75CA2301725Q37567714-091F279D-36A3-4B6F-B512-5DAF318E0F3AQ37685527-BDFBAABB-AC3D-4996-8F75-C99E6B0813E1Q37686026-0113F8EC-2C8F-4EE1-B987-391E9DDE0E95Q38087506-5CC25789-DED2-4050-82F6-C2783075E4EFQ38391516-696B80E5-D376-4A0C-823B-03B7F879AB30Q38689784-5511C063-3030-4B75-8A98-FDAD9455E8E2Q39360775-A1DA0D78-9749-42A3-8FD3-59FFB08686BBQ40079085-ACE70875-5CFB-4E61-A239-C6F30D64CF13Q43671010-41E07B4F-4855-4D8C-A63A-9A59B8AD9F65Q51119875-D44CA4CD-8E68-43E2-9662-D4B91BA48228Q51632815-43F28F98-CDAC-4F53-BD9D-2356407FA259Q53019116-19ED8A7C-4E12-46FD-BFBE-75C75AD85EBA
P2860
Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Immunoglobulin G Fc receptor F ...... s with non-Hodgkin's lymphoma.
@ast
Immunoglobulin G Fc receptor F ...... s with non-Hodgkin's lymphoma.
@en
type
label
Immunoglobulin G Fc receptor F ...... s with non-Hodgkin's lymphoma.
@ast
Immunoglobulin G Fc receptor F ...... s with non-Hodgkin's lymphoma.
@en
prefLabel
Immunoglobulin G Fc receptor F ...... s with non-Hodgkin's lymphoma.
@ast
Immunoglobulin G Fc receptor F ...... s with non-Hodgkin's lymphoma.
@en
P2093
P2860
P356
P1476
Immunoglobulin G Fc receptor F ...... s with non-Hodgkin's lymphoma.
@en
P2093
Philip Lavori
Robert S Negrin
Sandra J Horning
Wen-Kai Weng
P2860
P304
P356
10.1200/JCO.2009.25.0274
P407
P577
2009-11-23T00:00:00Z